TIRZ / IGF-1 LR3Check methods and identity
Why studies measure food intake separately from body weight
2 numbered sourcesSource years 1997, 2025
Peptides are short amino-acid chains linked by peptide bonds. Some work as signals that influence hunger or other physiological processes. Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended version of insulin-like growth factor 1. Older direct experiments on each component help explain why a study of the pair would need to measure food intake separately from weight and tissue outcomes. [1, 2]
In a randomized human study, investigators examined what participants ate at a laboratory lunch after assignment to tirzepatide or placebo. The researchers reported lower energy intake at that meal in the tirzepatide group at the study’s primary assessment. They also measured some aspects of hunger and cravings. A measured lunch and a report about appetite give distinct information. Neither alone describes all the food a person eats over weeks or months. [1]
In a separate older animal experiment, pigs exposed to IGF-1 LR3 ate less and gained less weight over the tested period. The researchers also observed changes in circulating hormones. The study involved a different species and did not administer tirzepatide. Weight gain and food intake can change together, so recording both allows investigators to examine possible explanations for a result. It does not prove that a particular tissue changed directly in response to the growth factor. [2]
A study that included both compounds would need to measure what the participants ate, how their weight changed, and which tissues or functions changed if those were the outcomes of interest. The existing studies describe different measures for each ingredient separately. They provide no evidence that adding one molecule to the other would produce a predictable change in appetite, growth or body composition. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
